Literature DB >> 11929384

Review article: faecal markers in the assessment of activity in inflammatory bowel disease.

A Poullis1, R Foster, T C Northfield, M A Mendall.   

Abstract

The fundamental pathological process behind ulcerative colitis and Crohn's disease is intestinal inflammation. As the precise cause of this is not yet completely understood, current treatment strategies are aimed at reducing or eliminating the inflammation. Endoscopic examination and histological analysis of biopsy specimens remain the 'gold standard' methods for detecting and quantifying bowel inflammation; however, these techniques are costly, invasive, and repeated examinations are unpopular with patients. Disease activity questionnaires and laboratory 'inflammatory markers', although widely used, show an unreliable correlation with endoscopy and histology. New markers need to be developed to detect and quantify bowel inflammation. These would be of use diagnostically and also an aid to pharmacological treatment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11929384     DOI: 10.1046/j.1365-2036.2002.01196.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  18 in total

Review 1.  Current advantages in the application of proteomics in inflammatory bowel disease.

Authors:  Anna Vaiopoulou; Maria Gazouli; George Theodoropoulos; George Zografos
Journal:  Dig Dis Sci       Date:  2012-06-28       Impact factor: 3.199

2.  Calprotectin: a novel noninvasive marker for intestinal allograft monitoring.

Authors:  Debra Sudan; Luciano Vargas; Yimin Sun; Lisette Bok; Gerard Dijkstra; Alan Langnas
Journal:  Ann Surg       Date:  2007-08       Impact factor: 12.969

3.  Urinary calprotectin and the distinction between prerenal and intrinsic acute kidney injury.

Authors:  Frank Heller; Sandra Frischmann; Maria Grünbaum; Walter Zidek; Timm H Westhoff
Journal:  Clin J Am Soc Nephrol       Date:  2011-09-01       Impact factor: 8.237

Review 4.  Noninvasive methods in evaluation of inflammatory bowel disease: where do we stand now? An update.

Authors:  Cansel Turkay; Benan Kasapoglu
Journal:  Clinics (Sao Paulo)       Date:  2010-02       Impact factor: 2.365

5.  Does calprotectin level identify a subgroup among patients suffering from irritable bowel syndrome? Results of a prospective study.

Authors:  Chloé Melchior; Moutaz Aziz; Typhaine Aubry; Guillaume Gourcerol; Muriel Quillard; Alberto Zalar; Moïse Coëffier; Pierre Dechelotte; Anne-Marie Leroi; Philippe Ducrotté
Journal:  United European Gastroenterol J       Date:  2016-06-23       Impact factor: 4.623

Review 6.  Fecal calprotectin: its scope and utility in the management of inflammatory bowel disease.

Authors:  Shapur Ikhtaire; Mohammad Sharif Shajib; Walter Reinisch; Waliul Islam Khan
Journal:  J Gastroenterol       Date:  2016-02-20       Impact factor: 7.527

Review 7.  The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease.

Authors:  James D Lewis
Journal:  Gastroenterology       Date:  2011-05       Impact factor: 22.682

8.  Crohn's disease patients have more IgG-binding fecal bacteria than controls.

Authors:  Hermie J M Harmsen; Simon D Pouwels; Anouk Funke; Nicolaas A Bos; Gerard Dijkstra
Journal:  Clin Vaccine Immunol       Date:  2012-02-15

9.  Validation and clinical significance of a new calprotectin rapid test for the diagnosis of gastrointestinal diseases.

Authors:  A Damms; S C Bischoff
Journal:  Int J Colorectal Dis       Date:  2008-07-16       Impact factor: 2.571

10.  Salmonella induces prominent gene expression in the rat colon.

Authors:  Wendy Rodenburg; Jaap Keijer; Evelien Kramer; Susanne Roosing; Carolien Vink; Martijn B Katan; Roelof van der Meer; Ingeborg M J Bovee-Oudenhoven
Journal:  BMC Microbiol       Date:  2007-09-12       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.